TABLE 2.
Multivariable analysis of Metabolic Syndrome and its components and NODAT
| Unadj. HR (lcl – ucl) | p | Adj. HR Met. Syndrome | p | Adj. HR Components of Met. Syndrome | p | |
|---|---|---|---|---|---|---|
| Age by decade | 1.31 (1.18- 1.46) | <0.0001 | 1.34 (1.20 - 1.50) | <0.0001 | 1.35 (1.21- 1.51) | <0.0001 |
| African American | 1.19 (0.89- 1.59) | 0.23 | 1.35 (1.01 - 1.82) | 0.043 | 1.37 (1.01 - 1.85) | 0.043 |
| Female Gender | 0.78 (0.59- 1.04) | 0.09 | ||||
| Hepatitis C seropositive | 1.52 (1.03- 2.24) | 0.03 | ||||
| Cytomegalovirus seropositive | 1.12 (0.81- 1.54) | 0.50 | ||||
| Tacrolimus use | 1.29 (0.75- 2.22) | 0.36 | ||||
| Metabolic Syndrome | 1.36 (1.02- 1.82) | 0.03 | 1.34 (1.00 - 1.79) | 0.047 | ||
| BMI ≥ 30 | 1.32 (0.99- 1.75) | 0.06 | ||||
| Glucose ≥ 100 | 1.36 (1.00- 1.86) | 0.05 | ||||
| HDL<50 W or 40 M | 1.35 (1.00- 1.81) | 0.05 | 1.37 (1.01 - 1.85) | 0.042 | ||
| Triglycerides ≥ 150 | 1.27 (0.96- 1.69) | 0.09 | ||||
| Systolic BP | 1.01 (1.00- 1.02) | 0.01 | ||||
| Albumin | 0.73 (0.32- 1.68) | 0.46 | ||||
| Apo A1 | 1.00 (0.99- 1.00) | 0.22 | ||||
| Etiology of PKD | 1.01 (0.67- 1.53) | 0.95 | ||||
| Deceased Donor | 1.33 (0.99- 1.78) | 0.05 | ||||
| Prednisone usea | 1.16 (1.05- 1.28) | 0.005 | 1.18 (1.07 - 1.30) | 0.001 | 1.18 (1.07 - 1.30) | 0.001 |
a
Prednisone use is defined as cumulative prednisone dosage in grams